100% Quality Guarantee
PhD-Level Technical Support
Gremubamab Antibody - bioactivity-binding
Key Features

Gremubamab Antibody (GXBS00482)

SKU GXBS00482
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Human
Reactivity Pseudomonas aeruginosa
Applications ELISA, FACS, Functional assay, Research in vivo
Isotype VH-CH1-VH-V-KAPPA-CH2-CH3
$409 - $1,138

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Gremubamab Antibody

Gremubamab Antibody is a research-grade biosimilar monoclonal antibody targeting PcrV & Psl. Format: VH-CH1-VH-V-KAPPA-CH2-CH3 (humanized host). Reactivity: Pseudomonas aeruginosa. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections. • A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis., PMID:38754132 • Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates., PMID:30016475 • Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide., PMID:26333940 • Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults., PMID:30107283 • AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia., PMID:38678160 • Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature., PMID:28463232 • Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models., PMID:31160288 • Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets., PMID:30185667 • Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice., PMID:33147726 • Antivirulence Bispecific Monoclonal Antibody-Mediated Protection against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model., PMID:34902264

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose